Pmda - Pharmaceuticals and Medical Devices Agency

Jump to body

Navigation of each product type

Our recommended contents

Navigation of each product type

Our recommended contents

日本語ページはこちら

Home
Post-marketing Safety Measures
Information Services
Drugs
MHLW Pharmaceuticals and Medical Devices Safety Information
MHLW Pharmaceuticals and Medical Devices Safety Information (FY2021)

Here begins the text.

MHLW Pharmaceuticals and Medical Devices Safety Information (FY2021)

FY 2021 (No.382-)

Japanese version issued on	No.	Table of contents	Posted on	PDF
July 13, 2021	384	Blood Monitoring and Rechallenge with Clozapine Important Safety Information Pembrolizumab (genetical recombination) Ixekizumab (genetical recombination) Revision of Precautions (No. 324) Diclofenac etalhyaluronate sodium (and 3 others) List of Products Subject to Early Post-marketing Phase Vigilance	Jul 13, 2021	(Full text)
June 10, 2021	383	MID-NET (Medical Information Database NETwork) Revision of Precautions (No. 323) Shosaikotokakikyosekko List of Products Subject to Early Post-marketing Phase Vigilance	Jun 10, 2021	(Full text)
April 27, 2021	382	PI (Package insert)-navi: A Smartphone App Designed for Digitized Package Inserts Digitization of Reports from Medical Institutions on Adverse Drug Reactions and Post-vaccination Suspected Adverse Reactions Important Safety Information Ritodrine hydrochloride (injections) Durvalumab (genetical recombination) Onasemnogene abeparvovec Revision of Precautions (No. 322) Magnesium sulfate hydrate/glucose (preparations indicated for prophylaxis and treatment of eclampsia in severe hypertensive disorders of pregnancy) (and 8 others) List of Products Subject to Early Post-marketing Phase Vigilance	Apr 27, 2021	(Full text)

Post-marketing Safety Measures

Pmda - Pharmaceuticals and Medical Devices Agency

JCN 3010005007409

Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki,
Chiyoda-ku, Tokyo 100-0013 Japan

Copyright (C) Pharmaceuticals and Medical Devices Agency, All Rights Reserved.

000048431

0

MHLW Pharmaceuticals and Medical Devices Safety Information (FY2021)

/english/safety/info-services/drugs/medical-safety-information/0019.html

en